Want to find your lens? Five questions, no jargon — they tell you which of four reads fits how you already think.
A wonderful business — priced for growth it hasn't delivered.
A great company, but no margin of safety at this price. Worth watching, not worth buying here.
The five checks
1 good · 2 caution · 2 warning
- WarningOvervaluedFair value ~$29 vs $315 — trading 91% above what the math supports.
- WarningPrice assumes a big accelerationYou'd need ~37%/yr free-cash-flow growth to justify today's price; it has done -25.2%/yr lately.
- GoodRevenue still growingUp 33.5% last year — demand isn't the problem.
- CautionCash flow flat-to-downFree cash flow ~-25.2%/yr — big, but not compounding. The crux for a value buyer.
- CautionManageable net debtNet debt of $0B — about 0.8× annual free cash flow. Normal for a mature company.
Price against fair value
What today's price assumes
Hold the price fixed and work backwards: how fast would free cash flow have to grow for $315 to make sense?
Price assumes a big acceleration.
How fair value is calculated
No analyst forecasts, no black box, no AI. Six lines from the filing to the answer.
- Free cash flow, typical yearThe five-year norm, from the annual reports$130M
- Ten years of it, growing 5% a year, each counted 9% lessThe same growth and discount for every company$1,064M
- Everything after year tenGrowing 2.5% a year, counted the same way+ $1,411M
- The business, in today's money$2,475M
- Subtract net debtBorrowings and finance leases less cash and securities− $100M
- Divide by the shares on file÷ 82.4M
Fair value per share$29
If our assumptions are wrong
Fair value per share under a faster or slower decade, and a gentler or harsher discount. The corners are where the $21 to $41 range comes from.
| 3% growth | 5% growth | 7% growth | |
|---|---|---|---|
| 8% discount | $29 | $35 | $41 |
| 9% discount | $25 | $29 | $34 |
| 10% discount | $21 | $25 | $29 |
The blue cell is the published method. Every cell sits below today’s price.
Free cash flow, ten years
$ billions · Form 10-K
What the math is really telling you. Watch whether cash flow is compounding — that, more than any single year, is what a value read hangs on.
How this was built. Every figure is computed from Axon Enterprise, Inc.'s SEC filings — no estimates, no AI. Two-stage DCF: 9% discount rate, 5% free-cash-flow growth for 10 years, 2.5% terminal. Free cash flow is operating cash flow less capital spending. Fair value is based on typical free cash flow over the last five years ($0.1B), not the latest year ($0.1B), which sat 38% below the company's own norm. Net cash is cash and marketable securities less borrowings, commercial paper and finance leases; operating leases are disclosed but never counted as debt. Fundamentals are from the FY25 annual report and change only when a new one is filed. Price of $315.43 taken 2026-11-15 (Google Finance, manual entry, 2026-11-13) — it is not live and does not move during the day.
Read Axon another way
TickerMath is an educational tool, not investment advice — it computes one model from SEC filings and can be wrong. How we compute this →